Cargando…

Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study

PURPOSE: Statins’ cholesterol-lowering efficacy is well-known. Recent epidemiological studies have found that inhibition of cholesterol synthesis may have beneficial effects on prostate cancer (PCa) patients, especially patients treated with androgen deprivation therapy (ADT). We evaluated statins’...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peltomaa, A. I., Raittinen, P., Talala, K., Taari, K., Tammela, T. L. J., Auvinen, A., Murtola, T. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384625/ https://www.ncbi.nlm.nih.gov/pubmed/33790420 http://dx.doi.org/10.1038/s41391-021-00351-2

Ejemplares similares

Statin use and outcomes of oncological treatment for castration-resistant prostate cancer
por: Peltomaa, A. I., et al.
Publicado: (2023)

Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level
por: Peltomaa, Antti I., et al.
Publicado: (2022)

Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer
por: Kinnunen, Pete T. T., et al.
Publicado: (2017)

Outcomes of prostate cancer screening among men using antidiabetic medication
por: Vettenranta, A., et al.
Publicado: (2021)

Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer
por: Kaapu, Kalle J, et al.
Publicado: (2016)

Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial
por: Veitonmäki, Thea, et al.
Publicado: (2016)

Antihypertensive drug use and prostate cancer-specific mortality in Finnish men
por: Siltari, Aino, et al.
Publicado: (2020)

Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer
por: Salminen, Jukka K., et al.
Publicado: (2022)

Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer
por: Murtola, Teemu J., et al.
Publicado: (2018)

Prostate cancer incidence in men with prostate‐specific antigen below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer
por: Ola, Idris Olasunmbo, et al.
Publicado: (2022)

Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men
por: Kaapu, Kalle J., et al.
Publicado: (2018)

Charlson Comorbidity Index Based On Hospital Episode Statistics Performs Adequately In Predicting Mortality, But Its Discriminative Ability Diminishes Over Time
por: Pylväläinen, Juho, et al.
Publicado: (2019)

Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial
por: Veitonmäki, T, et al.
Publicado: (2014)

Prostate cancer risk prediction using a polygenic risk score
por: Sipeky, Csilla, et al.
Publicado: (2020)

Long‐term health‐related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancer
por: Talala, Kirsi, et al.
Publicado: (2020)

Adaptive and non-adaptive gene expression responses in prostate cancer during androgen deprivation
por: Nätkin, Reetta, et al.
Publicado: (2023)

Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial
por: Murtola, T J, et al.
Publicado: (2009)

Atorvastatin induces adrenal androgen downshift in men with prostate cancer: A post Hoc analysis of a pilot adaptive Randomised clinical trial
por: Raittinen, Paavo V.H., et al.
Publicado: (2021)

Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol
por: Siltari, Aino, et al.
Publicado: (2022)

Prognostic Index for Predicting Prostate Cancer Survival in a Randomized Screening Trial: Development and Validation
por: Neupane, Subas, et al.
Publicado: (2021)

Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data
por: Booth, Neill, et al.
Publicado: (2019)

Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer
por: Jung, Jaeyoon, et al.
Publicado: (2015)

Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system
por: Eskelinen, Tommi, et al.
Publicado: (2021)

False-positive screening results in the Finnish prostate cancer screening trial
por: Kilpeläinen, T P, et al.
Publicado: (2010)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

High prevalence of vertebral fractures at initiation of androgen deprivation therapy for prostate cancer
por: van Oostwaard, Marsha M., et al.
Publicado: (2022)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

Pharmacoepidemiological Evaluation in Prostate Cancer—Common Pitfalls and How to Avoid Them
por: Siltari, Aino, et al.
Publicado: (2021)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Circulatory and prostatic tissue lipidomic profiles shifts after high-dose atorvastatin use in men with prostate cancer
por: Raittinen, Paavo, et al.
Publicado: (2020)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Biomarkers of Response to Neoadjuvant Androgen Deprivation in Localised Prostate Cancer
por: Pechlivanis, Maree, et al.
Publicado: (2021)

The Effects of Statins on Prostate Cancer Patients Receiving Androgen Deprivation Therapy or Definitive Therapy: A Systematic Review and Meta-Analysis
por: Hou, Yu-Chen, et al.
Publicado: (2022)

Metabolomic effects of androgen deprivation therapy treatment for prostate cancer
por: Chi, Jen‐Tsan, et al.
Publicado: (2020)

Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy
por: Siddiqui, Zaid A., et al.
Publicado: (2018)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Androgen deprivation and SARS-CoV-2 in men with prostate cancer
por: Koskinen, M., et al.
Publicado: (2020)

Androgen Deprivation-Induced Senescence Promotes Outgrowth of Androgen-Refractory Prostate Cancer Cells
por: Burton, Dominick G. A., et al.
Publicado: (2013)

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_stq8l4796e1kqhgc62geuu3ooe